Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Abstract JX-594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemotherapy has shown preclinical synergy with oncolytic viruses. We report here the results of the METROMAJX which is a randomized phase II clinical trial investigating the combi...

Full description

Bibliographic Details
Main Authors: Maud Toulmonde, Sophie Cousin, Michèle Kind, Jean-Philippe Guegan, Alban Bessede, Francois Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera, Antoine Italiano
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Hematology & Oncology
Subjects:
Soft-tissue sarcoma
Virus oncolytics
JX-594
Low-dose cyclophosphamide
Online Access:https://doi.org/10.1186/s13045-022-01370-9

Similar Items

Similar Items